Q-omics provides the consensus-scored ALMS1P1 profile across patient tissues and cancer cell-line models. ALMS1P1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, ALMS1P1 is differentially expressed in 11, with the highest sampling consensus in KICH. Additionally, ALMS1P1 RNA expression shows 19,731 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight BLCA, KICH, and UVM as cancer lineages where ALMS1P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ALMS1P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ALMS1P1 survival associations across molecular data types. ALMS1P1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ALMS1P1 RNA expression–survival associations across cancer types. High ALMS1P1 expression shows unfavorable associations in ACC and DLBC, but favorable associations in BLCA, KIRC, LGG and READ. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify BLCA as the clearest survival context for ALMS1P1 RNA expression.
This table summarizes ALMS1P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for ALMS1P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ALMS1P1 shows lower tumor expression in KICH, COAD, KIRP and THCA and higher tumor expression in KIRC and BLCA. The KICH box plot shows higher ALMS1P1 RNA expression in normal versus tumor tissue (log2 FC = −0.740, t-test p < 0.001).
This table shows molecular features associated with ALMS1P1 in patient tissues and cancer cell lines. In patient samples, ALMS1P1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ALMS1P1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in BONE.
